genOway (NYSE Alternext: ALGEN) is a public company focused on the development of custom genetically-modified (GM) mouse, rat and cellular models. In addition to providing highly advanced technological solutions for transgenesis and model design, genOway offers interactive scientific consulting at every step of the process. genOway considers its interactive consulting an essential part of the design process. genOway utilizes its consultation services to better understand your specific research needs, objectives and goals as well as to help enhance the reliability of your in vivo and in vitro studies.
genOway guarantees its clients exclusive access to key technologies in the field and/or provides its clients with the rights to all technologies and tools proposed and developed.
genOway generated more than 2000 genetically-modified models in the past 19 years while working with more than 170 Life Sciences companies and 380 academic institutes. Currently genOway collaborates with 15 of the Top 20 pharmaceutical companies worldwide and 11 universities from the Top 15 US National Ranking.
Board of Directors
- Christian Grenier
- Dr Alexandre Fraichard
- Michel G. Lurquin
- Denis Soubeyran
- André Tartar
- Robert Léon (represents FINOWAY/QUALIS SCA)
- Olivier Costa De Beauregard (represents Dassault Développement)
- Laurent Fraisse
Christian Grenier - Chairman of the board
After graduating fom ESCP and INSEAD, Christian Grenier began at McKinsey & Co as a stategy consultant. From 1987 onwards he successively lead 4 subsidiaries of the Rhone-Poulenc Aventis Group. He then co-founded the biotechnology company Urogène sold 7 years later to the Pierre Fabre Group. For 5 years he will then be leading the International Forum Biovision at Lyon gathering the major international leaders in the life sciences field (scientists, industrials or politicians) while being as well an operating partner at Advent International, a private equity firm in the pharma-chemistry industry.
Christian Grenier was Chairman of the Supervisory Board or Director of many biotechnology companies (Neorphys, Cytomix System, Watchfrog). He currently is the Director of Delpharm.
Alexandre Fraichard - MBA HEC – General Manager
French. Earned his Ph.D. at the Ecole Normale Supérieure de Lyon in Molecular and Cellular Biology in 1997. Worked for five years on animal models at the ENS where he produced the first model of hypothyroidism and co-founded the Transgenetic Center.
Did an MBA (1998-1999) at the HEC business school (Paris, France) and co-founded genOway in 1999.
Michel G. Lurquin
Belgian. Former Director & Vice President Europe for Technical Operations at SmithKlineBeecham and more recently Senior Vice President of UCB covering Global Technical & Supply Operations ( Chemical & Pharmaceutical Development, Manufacturing, as well as Purchasing and Supply activities worldwide).
Former Expert with the EBRD (European Bank for Reconstruction and Development), during his career with SmithKlineBeecham filled a number of positions in Regulatory, Quality and Technical Operations.
Founder of NCM Life Sciences, he has been actively participating in the development of other start-ups in the healthcare sector such as Bioprofile and Biomethodes. He is also currently Non Executive Director of Neolix SAS
Denis Soubeyran is a graduate of Ecole Normale Supérieure, the French National School of Management (ENA) and Harvard Business School.
Denis' career began as Senior Auditor in the French National Audit Office with several missions. He was then dispatched for 1 year to the National Audit Office (UK), 3 years to the French Ministry of Finance and 2 years to the French National Space Agency.
Before joining LFB SA, Denis was the Head of Financial Operations Department and member of the Management Committee for Americas of Renault, the French car manufacturer, from 2000 to 2009.
Prior to that, he spent 4 years as Deputy to the Group Controller and then Chief Financial Officer for Renault Samsung Motors in South Korea.
Since 2010, he serves as CFO of LFB SA, a French pharmaceutical company specializing in the development, manufacturing and marketing of drugs for rare diseases. He is in charge of corporate strategy, planning, controlling, accounting, tax and IT.
Andre Tartar, PharmD-PhD, is Professor at the Faculty of Pharmacy in Lille since 1981. He is in charge since 1998 of the training of the industrial pharmacists. He is the past president of the “Société de Chimie thérapeutique”. He chairs the scientific board of Paris Biotech Santé, the incubator for start-up companies in Paris. He is a consultant in preclinical research for several pharmaceutical and biotechnological companies (Ferring, Diverchim, Orphelia, Septeos…). From 1999 to 2004, he was director of Chemistry at the Ferring Research Institute in Chilworth. From 1996 to 1998, he was co-founder and CSO of CEREP, a public company specialised in HTS and HTOS technologies. From 1986 to 1996, he was the founder and chairman of the department of Bioorganic Chemistry at the Pasteur Institute of Lille. From 1982 to 1986, he was in charge of a CNRS research unit at the Faculty of Pharmacy in Lille specialized in peptides. During his career, he published more than 230 research papers in the fields of bioorganic and medicinal chemistry (Nature, Science, JACS, JOC, PNAS, J Exp Med...) and received numerous patents.
Olivier Costa De Beauregard, represents Dassaut Développement
Alumnus of the Ecole Normale Superieure and the Ecole Nationale d'Administration, Honorary Finance Inspector and Technical Advisor for the Cabinet of the Prime Minister from 1993-1995, Mr. Costa Beauregard then held management positions in the AXA Group and HSBC France. In December 2005, he joined the Dassault Group (Groupe Industriel Marcel Dassault - GIMD) as their Managing Director.
Laurent Fraisse earned his PhD in Biotechnology at the Institut National Polytechnique de Toulouse, France, and went on to hold various positions at Technical University Munich, Germany, and Lacq Research Center, France. For the next 10 years, he led a group at Sanofi-Aventis, successfully developing research strategies for tuberculosis, malaria and hospital-treated infections, before becoming research director and deputy head of the EIM (Exploratory and Internal Medicine International Department) global leadership team and member of the global Discovery Research Board at Sanofi, Toulouse, France. Since 2010, he has held leading positions at the Infectious Disease Therapeutic Strategic Unit at Sanofi, Toulouse, and served as Vice President of R&D and Global Head of the Infectious Diseases Therapeutic Area. In July 2018, he became Executive Vice President for Infectious Diseases R&D at Evotec, Lyon, France.
Auditor & legal advisor: Avvens (member of Crowe Horwarth International)
Patent attorney M. Warcoin CEO of Cabinet Regimbeau, a leading European patent attorney is advising the company on its intellectual property policy including patents, licensing out and licensing in.